시장보고서
상품코드
1429326

세계 항 천식제 및 COPD 약물 시장 보고서(2024년)

Anti-Asthmatics And COPD Drugs Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

항 천식제 및 COPD 약물 시장 규모는 향후 몇 년동안 상당한 성장이 예상됩니다. 2028년 복합 연간 성장률(CAGR) 6.3%를 나타낼 전망이며 1,041억 달러로 성장할 것으로 예상됩니다. 항 천식제와 COPD 치료제의 성장이 기대되는 배경으로는 전자담배의 보급, 비만 증가, 기술의 진보, 진단되지 않은 인구, COVID-19의 치료에 있어서의 약제의 사용 등의 요인이 있습니다. 주요 동향으로는 천식 치료제의 프로바이오틱스, 포트폴리오 확대를 위한 항IL-5 약물, 혁신적인 제품의 상시, 생체전기약에 대한 투자 증가, 사업 확대를 위한 공동 노력, 개별 화 의료 탐구, 에어로졸 호흡기 치료제에 대한 투자, 효과적인 의약품 개발을 위한 바이오마커 연구, 경쟁을 위한 제네릭 의약품에 대한 주력, 병용약의 개발, 생물제제의 생산 등을 들 수 있습니다.

흡연, 앉아 있는 라이프스타일, 건강에 해로운 식생활과 같은 수정 가능한 위험 요소는 항 천식제 및 COPD 약물 시장 추진에 크게 기여하고 있습니다. 세계적으로 흡연률이 떨어지고 있는 반면 중국, 인도, 인도네시아, 나이지리아 등 특정 개발도상국에서는 흡연률이 상승하는 경향이 있습니다. 예를 들어 인도네시아에서는 2025년까지 흡연자가 2,400만 명 증가할 것으로 예상되고, 나이지리아에서는 흡연자가 700만 명 증가할 것으로 예상됩니다. 또한 중국은 세계 담배 소비량의 40% 이상을 차지하고 있습니다. 건강에 해로운 다이어트 습관, 특히 미국과 유럽과 같은 고소득 국가에서 만연하는 지방과 포화 지방산의 다량 섭취는 천식과 COPD와 관련된 위험 요인의 원인이되었습니다. WHO의 데이터는 선진국에서는 에너지 섭취량의 35% 이상이 지방 유래인 반면 저소득 국가에서는 20% 미만, 하위 중소득 국가에서는 25% 미만임을 부각하고 있습니다.

천식성 질환의 만연은 항 천식제 및 COPD 약물 시장 성장의 원동력이 될 것으로 예상됩니다. 기도의 염증과 협착을 특징으로 하는 만성 질환인 천식은 증례 수가 증가하는 경향이 있으며, 이러한 질환을 관리하기 위한 새로운 약물의 확인과 개발이 촉진되고 있습니다. 예를 들어(2022년) 4월 국민건강면접조사(NHIS)의 데이터에 근거하면, 2020년 미국에서는 18세 이하의 어린이의 약 42.7%, 5세 미만의 어린이의 약 52.9%가 천식을 앓고 있다 라고 보고되었습니다. 천식 환자 증가는 혁신적인 의약품의 지속적인 개발을 자극하고 항 천식 및 COPD 약물 시장을 추가로 추진할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나,러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계 시장 규모 실적과 성장(2018년-2023년)
  • 세계 시장 규모 예측과 성장(2023년-2028년, 2033년)

제6장 시장 세분화

  • 세계 항 천식제 및 COPD 약물 시장, 유형별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 항히스타민제
  • 장시간 작용형 B2 효능제(LABA)
  • 흡입 코르티코스테로이드
  • 단시간 작용형 무스카린 수용체 길항제(SAMA)
  • 기타 항 천식제 및 COPD 약물(조합 포함)
  • 세계 항 천식제 및 COPD 약물 시장, 유통 채널별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 병원 약국
  • 프라이빗 클리닉
  • 약국
  • 소매 약국
  • 전자상거래
  • 세계 항 천식제 및 COPD 약물 시장 : 최종 사용자별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 천식환자
  • COPD 환자

제7장 지역 및 국가 분석

  • 세계 항 천식제 및 COPD 약물 시장 : 지역별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 세계 항 천식제 및 COPD 약물 시장 : 국가별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 항 천식제 및 COPD 약물 시장 경쟁 구도
  • 항 천식제 및 COPD 약물 시장 기업 프로파일
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Boehringer Ingelheim GmbH
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG

제31장 기타 선도적이고 혁신적인 기업

  • Sanofi SA
  • Chiesi Farmaceutici SpA
  • Teva Pharmaceutical Industries Limited
  • Merck &Co. Inc.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • China National Pharmaceutical Group Co. Ltd.(Sinopharm)
  • Shanghai Acebright Pharmaceuticals Group Co. Ltd.
  • Jiangsu Hengrui Medicine Co. Ltd
  • Hanmi Pharmaceutical
  • Cipla Limited
  • Aurobindo Pharma Limited
  • KYORIN Holdings Inc.
  • Nichi-Iko Pharmaceutical Co. Ltd.
  • Otsuka Pharmaceutical Co. Ltd.
  • Daewoong Pharmaceutical Co. Ltd

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망과 가능성 분석

제36장 부록

BJH 24.03.21

Anti-asthmatic and chronic obstructive pulmonary disease (COPD) drugs are medications designed to alleviate the frequency of acute attacks in conditions such as asthma, emphysema, chronic bronchitis, and nocturnal awakenings.

The primary classes of drugs in anti-asthmatics and COPD include bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. Bronchodilators stimulate the bronchi and bronchioles, reducing respiratory airway resistance and enhancing lung airflow. Various types of bronchodilators include anti-histamine drugs, long-acting B2-agonists (LABA), inhaled corticosteroids, short-acting muscarinic receptor antagonists (Samas), and other combinations of anti-asthmatics and COPD drugs. These medications are utilized by asthma and COPD patients and are distributed through diverse channels such as hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce platforms.

The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market research report are one of a series of new reports from The Business Research Company that provides anti-asthmatics and chronic obstructive pulmonary disease (COPD) market statistics, including anti-asthmatics and chronic obstructive pulmonary disease (COPD) industry global market size, regional shares, competitors with an anti-asthmatics and chronic obstructive pulmonary disease (COPD) market share, detailed anti-asthmatics and chronic obstructive pulmonary disease (COPD) market segments, market trends and opportunities, and any further data you may need to thrive in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) industry. These anti-asthmatics and chronic obstructive pulmonary disease (COPD) market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-asthmatics and copd drugs market size has grown strongly in recent years. It will grow from $76.16 billion in 2023 to $81.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth observed in the historical period in the field of anti-asthmatic and chronic obstructive pulmonary disease (COPD) drugs can be attributed to several key factors. These include an increased prevalence of respiratory diseases, a rise in tobacco smoking incidence, global warming implications, a growing geriatric population, emerging markets, innovative methods for drug discovery, and an overall increase in healthcare expenditure. These factors collectively contributed to the expansion of the market, reflecting the heightened focus on respiratory health, evolving treatment methods, and the impact of demographic and environmental factors on respiratory conditions.

The anti-asthmatics and copd drugs market size is expected to see strong growth in the next few years. It will grow to $104.1 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. Anticipated growth in anti-asthmatic and COPD drugs is driven by factors such as the popularity of e-cigarettes, rising obesity, technological advancements, undiagnosed populations, and the drugs' use in treating COVID-19. Key trends include probiotic drugs for asthma, anti-IL-5 drugs for portfolio expansion, innovative product launches, increased investments in bioelectric medicines, collaborative efforts for business expansion, exploration of personalized medicine, investment in aerosol respiratory drugs, biomarker research for effective drug development, focus on generic drugs for competition, development of combination drugs, and production of biologics.

Modifiable risk factors such as smoking, sedentary lifestyles, and unhealthy dietary habits significantly contribute to driving the anti-asthmatics and copd drugs market. While smoking rates are declining globally, certain developing nations such as China, India, Indonesia, and Nigeria are witnessing an upward trend in smoking prevalence. For example, Indonesia is anticipated to see a rise of 24 million tobacco smokers by 2025, while Nigeria is expected to witness an increase of 7 million smokers. Additionally, China holds over 40% of global cigarette consumption. Unhealthy dietary practices, especially high consumption of fats and saturated fatty acids prevalent in high-income countries such as the USA and Europe, contribute to the risk factors associated with Asthma and COPD. WHO data highlights that in developed countries, over 35% of energy intake comes from fats, in contrast to less than 20% in low-income countries and below 25% in lower-middle-income countries.

The prevalence of asthmatic disorders is anticipated to be a driving force behind the growth of the anti-asthmatics and COPD drugs market. Asthma, a chronic condition characterized by airway inflammation and constriction, has shown an upward trend in cases, prompting the identification and development of new medications to manage these disorders. For example, based on data from the National Health Interview Survey (NHIS) in April 2022, approximately 42.7% of children aged 18 or younger and 52.9% of children under 5 years old were reported to have asthma in the United States in 2020. This rise in asthmatic cases is expected to stimulate the continuous development of innovative drugs, further propelling the anti-asthmatics and copd drugs market.

Numerous inhalers devoid of chlorofluorocarbons (CFCs) are presently accessible for managing asthma and chronic obstructive pulmonary disease (COPD). While these products might not be formally designated as direct replacements for CFC Metered Dose Inhalers, they can be considered beneficial medications for many patients, potentially eliminating the necessity for specific CFC Metered Dose Inhalers. The determination of official alternatives will be made by the FDA, employing criteria established via notice-and-comment rulemaking processes.

Major players within the anti-asthmatics and COPD drugs market are driving innovation with products such as the dose combination (FDC) drug, Indacaterol plus Mometasone, aiming to enhance their market position. This FDC medication, administered via the Breezhaler device, represents a once-daily treatment designed for ongoing asthma management in patients. Glenmark Pharmaceuticals, for instance, introduced the novel FDC drug named Indamet in India in June 2022. Available in three variations, Indamet maintains a consistent dose of 150 mcg of Indacaterol while varying Mometasone doses (80 mcg, 160 mcg, and 320 mcg strengths) to address uncontrollable asthma cases.

The trend toward combination therapies for asthma and COPD treatment is on the rise, showcasing greater efficacy in patient-reported outcomes (PROs) compared to monotherapies. Combinations such as short-acting beta-agonists (SABA) coupled with short-acting muscarinic antagonists (SAMA) have demonstrated superior effects on lung function when compared to individual medications. Similarly, the utilization of long-acting beta-agonists (LABA) paired with long-acting muscarinic antagonists (LAMA) has shown improved lung function in comparison to long-acting monotherapy bronchodilators.

Major companies operating in the anti-asthmatics and copd drugs market report are GlaxoSmithKline PLC, AstraZeneca PLC, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd., GSK, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd., Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Cipla Medpro South Africa (Pty) Limited, Aspen Nigeria

North America was the largest region in the anti-asthmatics and COPD drugs market in 2023. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and copd drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-asthmatics and copd drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The anti-asthmatic and chronic obstructive pulmonary disease market consists of corticosteroid, bronchodilator, fluticasone and salmeterol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Asthmatics And COPD Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-asthmatics and COPD drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-asthmatics and COPD drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-asthmatics and COPD drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Class: Bronchodilators; Anti-Inflammatory Drugs; Monoclonal Antibodies; Combination Drugs
  • 2) By Distribution Channel: Hospital Pharmacies; General Pharmacies; Online Retailers
  • 3) By End User: Asthma Patients; COPD Patients
  • 4) By Therapy: Preventive; Curative
  • 5) By Route Of Administration: Oral; Inhaled; Intravenous; Subcutaneous
  • 6) By Age Group: Below 5; 5-14; 15-60; Above 60
  • Companies Mentioned: GlaxoSmithKline plc; AstraZeneca plc; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anti-Asthmatics And COPD Drugs Market Characteristics

3. Anti-Asthmatics And COPD Drugs Market Trends And Strategies

4. Anti-Asthmatics And COPD Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Anti-Asthmatics And COPD Drugs Market Size and Growth

  • 5.1. Global Anti-Asthmatics And COPD Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Anti-Asthmatics And COPD Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Anti-Asthmatics And COPD Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anti-Asthmatics And COPD Drugs Market Segmentation

  • 6.1. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Anti-histamine Drugs
  • long-acting B2-agonists (LABA)
  • Inhaled corticosteroids
  • Short-acting muscarinic receptor antagonists (SAMAs)
  • Other Anti-Asthmatics And COPD Drugs (including Combinations)
  • 6.2. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce
  • 6.3. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Asthma Patients
  • COPD Patients

7. Anti-Asthmatics And COPD Drugs Market Regional And Country Analysis

  • 7.1. Global Anti-Asthmatics And COPD Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Anti-Asthmatics And COPD Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anti-Asthmatics And COPD Drugs Market

  • 8.1. Asia-Pacific Anti-Asthmatics And COPD Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anti-Asthmatics And COPD Drugs Market

  • 9.1. China Anti-Asthmatics And COPD Drugs Market Overview
  • 9.2. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anti-Asthmatics And COPD Drugs Market

  • 10.1. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anti-Asthmatics And COPD Drugs Market

  • 11.1. Japan Anti-Asthmatics And COPD Drugs Market Overview
  • 11.2. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anti-Asthmatics And COPD Drugs Market

  • 12.1. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anti-Asthmatics And COPD Drugs Market

  • 13.1. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anti-Asthmatics And COPD Drugs Market

  • 14.1. South Korea Anti-Asthmatics And COPD Drugs Market Overview
  • 14.2. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anti-Asthmatics And COPD Drugs Market

  • 15.1. Western Europe Anti-Asthmatics And COPD Drugs Market Overview
  • 15.2. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anti-Asthmatics And COPD Drugs Market

  • 16.1. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anti-Asthmatics And COPD Drugs Market

  • 17.1. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anti-Asthmatics And COPD Drugs Market

  • 18.1. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anti-Asthmatics And COPD Drugs Market

  • 19.1. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anti-Asthmatics And COPD Drugs Market

  • 20.1. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anti-Asthmatics And COPD Drugs Market

  • 21.1. Eastern Europe Anti-Asthmatics And COPD Drugs Market Overview
  • 21.2. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anti-Asthmatics And COPD Drugs Market

  • 22.1. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anti-Asthmatics And COPD Drugs Market

  • 23.1. North America Anti-Asthmatics And COPD Drugs Market Overview
  • 23.2. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anti-Asthmatics And COPD Drugs Market

  • 24.1. USA Anti-Asthmatics And COPD Drugs Market Overview
  • 24.2. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anti-Asthmatics And COPD Drugs Market

  • 25.1. Canada Anti-Asthmatics And COPD Drugs Market Overview
  • 25.2. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anti-Asthmatics And COPD Drugs Market

  • 26.1. South America Anti-Asthmatics And COPD Drugs Market Overview
  • 26.2. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anti-Asthmatics And COPD Drugs Market

  • 27.1. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anti-Asthmatics And COPD Drugs Market

  • 28.1. Middle East Anti-Asthmatics And COPD Drugs Market Overview
  • 28.2. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anti-Asthmatics And COPD Drugs Market

  • 29.1. Africa Anti-Asthmatics And COPD Drugs Market Overview
  • 29.2. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anti-Asthmatics And COPD Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Anti-Asthmatics And COPD Drugs Market Competitive Landscape
  • 30.2. Anti-Asthmatics And COPD Drugs Market Company Profiles
    • 30.2.1. GlaxoSmithKline plc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AstraZeneca plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Boehringer Ingelheim GmbH
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. F. Hoffmann-La Roche Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Anti-Asthmatics And COPD Drugs Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Chiesi Farmaceutici S.p.A.
  • 31.3. Teva Pharmaceutical Industries Limited
  • 31.4. Merck & Co. Inc.
  • 31.5. Sumitomo Dainippon Pharma Co. Ltd.
  • 31.6. China National Pharmaceutical Group Co. Ltd. (Sinopharm)
  • 31.7. Shanghai Acebright Pharmaceuticals Group Co. Ltd.
  • 31.8. Jiangsu Hengrui Medicine Co. Ltd
  • 31.9. Hanmi Pharmaceutical
  • 31.10. Cipla Limited
  • 31.11. Aurobindo Pharma Limited
  • 31.12. KYORIN Holdings Inc.
  • 31.13. Nichi-Iko Pharmaceutical Co. Ltd.
  • 31.14. Otsuka Pharmaceutical Co. Ltd.
  • 31.15. Daewoong Pharmaceutical Co. Ltd

32. Global Anti-Asthmatics And COPD Drugs Market Competitive Benchmarking

33. Global Anti-Asthmatics And COPD Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market

35. Anti-Asthmatics And COPD Drugs Market Future Outlook and Potential Analysis

  • 35.1 Anti-Asthmatics And COPD Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Anti-Asthmatics And COPD Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Anti-Asthmatics And COPD Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제